Dianthus Therapeutics Inc

+0.29 (+2.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Dianthus Therapeutics Inc Stock, :DNTH

7 Times Square, 43rd Floor, New York, New York 10036
United States of America
Phone: +1.929.999.4055
Number of Employees: 47


Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. Its lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology, enabling less frequent and more convenient self-administered subcutaneous injections to improve the lives of patients. The company was founded on June 17, 2015 and is headquartered in New York, NY.